Kodiak Sciences Inc.
HealthcareNASDAQ:KOD · NASDAQ Global Market
+$0.09 today
Vol 0.63M · Avg 1.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-146.1%
avg -47.3%
ROIC
-73.7%
avg -7.6%
ROA
-65.4%
avg -132.5%
Analysis
ROA is currently the strongest return metric at -65.4% versus its period average of -132.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President | $1.58M | — | 52 | $2.40M | 4.53% |
John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary | $937,157.00 | — | 63 | $216,034.00 | 0.41% |
Hong Liang | Senior Vice President of Development | $300,709.00 | — | 54 | $130,166.00 | 0.25% |
J. Pablo Velazquez-Martin | Chief Medical Officer | — | — | — | — | — |
Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing | — | — | — | — | — |
Laurent Ducry | Senior Vice President of Biologics Development & Manufacturing | — | — | — | — | — |
Almas Qudrat | Chief Quality Officer | — | — | — | — | — |
Wayne To | Chief Technology Officer | — | — | — | — | — |
Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing | — | — | — | — | — |
Dolly S. Chang | Chief Scientific Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$60.00M
Sells
7
$2.22M
Net Sentiment
+$57.78M
Net buying
Most Active
BORGESON JOHN A.
7 transactions
Analysis
Insiders reported 2 buys worth $60.00M and 7 sells worth $2.22M over the last 12 months. That adds up to net buying of $57.78M. BORGESON JOHN A. was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages KOD?
Kodiak Sciences Inc. (KOD) lists 10 active executives. The top listed executive is J. Pablo Velazquez-Martin, Chief Medical Officer.
Are KOD insiders buying or selling?
Recent insider activity shows net buying of $160.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.